Stockscreener 앱 받기
8.60
1.04%
-0.09
시간 외 거래:
8.60
전일 마감가:
$8.69
열려 있는:
$8.68
하루 거래량:
503.99K
Relative Volume:
0.69
시가총액:
$449.58M
수익:
$85.21M
순이익/손실:
$-140.11M
주가수익비율:
-3.42
EPS:
-2.5146
순현금흐름:
$-109.62M
1주 성능:
-6.01%
1개월 성능:
-12.24%
6개월 성능:
-20.66%
1년 성능:
+138.89%
1일 변동 폭
$8.55
$8.90
1주일 범위
$8.07
$9.35
52주 변동 폭
$3.365
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
8.60 | 454.28M | 85.21M | -140.11M | -109.62M | -2.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
Pittsburgh Post-Gazette - FinancialContent
4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - Insider Monkey
4D Molecular Therapeutics, Inc.Common Stock (NQ: FDMT - FinancialContent
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
About Us - FinancialContent
User | mammothtimes.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
User | malvern-online.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares - Stock Titan
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants - Stock Titan
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees - Stock Titan
Fat Pitch Financials4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
[EFFECT] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - MSN
FDMT: 4D-150's phase III progress and robust data position it as a potential game-changer in retinal gene therapy - TradingView
State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026 - Stock Titan
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report - simplywall.st
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged - TipRanks
4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
4D Molecular Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.62, Implies 178% Upside - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down After Earnings Miss - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) files $400M shelf registration - Stock Titan
Wet AMD gene therapy moves ahead; 4DMT targets 2027 Phase 3 data - Stock Titan
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
4D Molecular (NASDAQ: FDMT) details Q1 loss and cash runway to 2028 - Stock Titan
4D Molecular Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
4DMT management to present at BofA, RBC healthcare conferences - Stock Titan
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Thursday - MarketBeat
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Board moves key votes at 4D Molecular Therapeutics (NASDAQ: FDMT) 2026 meeting - Stock Titan
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
4D (FDMT) Stock Beneficial Ownership (Grinds Lower) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan
Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Will 4D (FDMT) Stock Hit Record Highs | Price at $9.48, Down 3.95%Crowd Trend Signals - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):